Patients in both repaglinide and metformin groups achieved significant reductions in HbA1c ( -1.8 1.5 vs -1.6 1.5 % ) , FPG ( fasting blood glucose ) ( -1.7 1.7 vs -2.1 1.7 mmol/l ) and 2-hPPG ( post-prandial glucose ) ( -3.8 3.1 vs -3.8 3.6 mmol/l ) , with no statistical differences between the groups .